239 related articles for article (PubMed ID: 31266752)
1. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
[TBL] [Abstract][Full Text] [Related]
2. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
[TBL] [Abstract][Full Text] [Related]
3. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
Liu L; Cheeti S; Yoshida K; Choo E; Chen E; Chen B; Gates M; Singel S; Morley R; Ware J; Sahasranaman S
J Clin Pharmacol; 2018 Nov; 58(11):1427-1435. PubMed ID: 29786857
[TBL] [Abstract][Full Text] [Related]
4. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
[TBL] [Abstract][Full Text] [Related]
5. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
6. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
7. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
8. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics.
Yoshida K; Guo C; Sane R
CPT Pharmacometrics Syst Pharmacol; 2018 Aug; 7(8):517-524. PubMed ID: 29924471
[TBL] [Abstract][Full Text] [Related]
12. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
13. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
[TBL] [Abstract][Full Text] [Related]
14. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
[TBL] [Abstract][Full Text] [Related]
15. Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.
Farasyn T; Crowe A; Hatley O; Neuhoff S; Alam K; Kanyo J; Lam TT; Ding K; Yue W
J Pharm Sci; 2019 Oct; 108(10):3443-3456. PubMed ID: 31047942
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
17. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
18. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
20. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]